I have read about this case. My understanding is that CSL was a candidate trying to produce a vaccine that was unsuccessful. The production facilities were there, CSL met the regulatory standards, which one of your clients emphasized as being very important, and the Australian government did, indeed, tie the procurement contract to a requirement for some degree of local manufacturing. Again, some hedging was built into this. This might be the type of flexible and smart procurement that could be done, but please note the prerequisite that the Australians had the facility in place before it could take this step.
On April 16th, 2021. See this statement in context.